Full-Time

Principal Scientist – Clinical Operations Immunology Lead

Updated on 8/6/2026

Deadline 8/9/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$210.4k - $331.1k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

Boston, MA, USA + 3 more

More locations: South San Francisco, CA, USA | West Point, PA, USA | Rahway, NJ, USA

Hybrid

Hybrid work is required; domestic relocation is available. Travel requirements are 10%.

Bachelor's, Master's, PharmD, PhD

Category
Biology & Biotech (1)

Get referred to Merck

See people who can refer or advise you

Requirements
  • A degree in Life Sciences with either a Bachelor’s degree and at least 16 years of related experience, a Master’s degree and at least 15 years of related experience, or a PhD or PharmD and at least 12 years of related experience.
  • Related experience includes pharmaceutical industry roles in clinical drug development, clinical trial management, clinical site monitoring or training, medical or regulatory writing, or translational science.
  • Extensive clinical operations experience planning and executing early clinical development trials, including Phase 1 and early proof-of-concept studies.
  • Ability to translate knowledge to other areas and effectively collaborate, network, and influence peers, senior leaders, and external partners.
  • A proven track record building and leading high-performing cross-functional teams in a matrixed environment.
  • Strong decision-making skills, including weighing advantages, disadvantages, and business impact to make rapid decisions and deliver results on firm deadlines.
  • Ability to work successfully with ambiguity and embrace uncertainty.
  • Strong oral and written communication skills.
  • Experience attracting, developing, and retaining talent.
  • Knowledge of clinical development, clinical research, clinical studies, clinical trial management, clinical trial planning, clinical trials, clinical trial operations, cross-cultural awareness, cross-functional teamwork, drug development, early clinical development, early-phase clinical trials, ethical compliance, ethical standards, external partners, mentorship, operational leadership, professional networking, protocol development, and translational medicine.
Responsibilities
  • Co-own and execute the early clinical development strategy for the immunology portfolio with the Head of Translational Medicine Immunology.
  • Provide strategic planning and operational oversight for immunology clinical programs and trials to maximize feasibility, efficiency, consistency, and quality across the portfolio.
  • Build a global network of immunology sites and foster relationships with key investigators for Phase 1b/2a patient trials.
  • Serve as the subject matter expert and issue-escalation point for early immunology clinical operations.
  • Ensure appropriate resources, competencies, and partnerships are in place to meet objectives.
  • Critically review development plans, investigator’s brochures, protocols, and other clinical program documents, providing scientific and operational insight.
  • Partner with Business Development and Licensing to evaluate internal and external opportunities aligned with portfolio strategy.
  • Participate in annual and quarterly planning cycles, identify risks, develop and execute mitigation plans, and track performance metrics and outcomes.
  • Ensure immunology data integrity across the organization, including Book of Business and Clinical Trial Management System data.
  • Build and sustain cross-functional relationships across country operations, clinical supplies, data management, regulatory, departments, divisions, and geographies.
  • Attract, coach, mentor, and retain talent; provide performance-management support; and act as a player-coach to enrich group skillsets.
  • Represent Translational Medicine on enterprise strategic initiatives and lead continuous-improvement efforts that increase clinical efficiency and scientific impact.
  • Serve as a member of the Translational Medicine Clinical Operations leadership team and contribute to department strategy.
Desired Qualifications
  • Experience leading clinical programs and trials in gastroenterology, dermatology, and/or rheumatology, especially autoimmune or immune-mediated disorders, in both large and small pharmaceutical contexts.
  • Familiarity with broader pharmaceutical industry considerations and trends beyond clinical development.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck raised 2026 revenue guidance to $66.3 billion-$67.3 billion on August 4, 2026.
  • WINREVAIR sales hit $588 million in Q2 2026, up 75% year over year.
  • CAPVAXIVE gained pediatric approval on August 4, 2026, expanding its market immediately.

What critics are saying

  • Keytruda biosimilars threaten December 2028 entry; Merck expects material sales decline by 2029.
  • HHS selected Keytruda for 2027 price-setting, cutting U.S. pricing from January 2029.
  • Keytruda drove $8.37 billion in Q2 2026; failed replacements break Merck's earnings model.

What makes Merck unique

  • Keytruda, Winrevair, and Capvaxive diversify Merck beyond one drug franchise.
  • Merck's Q2 2026 launch products produced $1.5 billion, proving repeatable commercialization.
  • The company pairs human health with animal health, adding $1.8 billion Q2 2026 revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
CNBC
Aug 4th, 2026
Merck raises revenue outlook to $67B on new drug growth, cuts profit guidance on $15B deal charges

Merck raised its 2026 revenue forecast to between $66.3 billion and $67.3 billion, up from a previous range of $65.8 billion to $67 billion. However, the company cut its adjusted earnings outlook to $2.66 to $2.76 per share, down from $5.04 to $5.16, due to one-time charges totalling $14.7 billion related to acquisitions of Terns and Cidara Therapeutics. For the second quarter, Merck reported $16.61 billion in revenue, up 5% year-over-year. Keytruda generated $8.37 billion in sales, whilst newer drugs showed strong growth. Winrevair sales reached $588 million, up 75%, and Capvaxive posted $184 million, up 42%. The company is acquiring businesses to offset upcoming generic competition for several drugs, including Keytruda in 2028.

Yahoo Finance
Aug 3rd, 2026
Merck Q2 earnings preview: analysts expect 3% revenue growth to $16.29B

Merck is set to announce its Q2 earnings on Tuesday before market hours. The market expects revenue to grow 3% year-on-year, reversing the 1.9% decrease recorded in the same quarter last year. Last quarter, Merck reported revenues of $16.29 billion, up 4.9% year-on-year, beating analysts' expectations. The company also exceeded EPS estimates. Analysts have generally reconfirmed their estimates over the last 30 days. Among peers, Corcept reported 7.3% revenue growth but missed estimates by 1%, whilst Bristol-Myers Squibb posted 5.7% growth, topping estimates by 12.9%. Merck's share price has risen 2.6% over the past month, with an average analyst price target of $135.19 compared to the current share price of $130.31.

Yahoo Finance
Jul 31st, 2026
Merck's strong 21.5% cash flow margin contrasts with Allegro and Viavi's struggles

StockStory analysed three cash-producing stocks, recommending investors avoid two while highlighting one with stronger prospects. Allegro MicroSystems faces end-market challenges, with flat sales over two years and operating margin falling to 2% over five years. The power management chip designer trades at 37.6x forward P/E. Viavi Solutions showed weak performance with 3.4% annual growth over five years, whilst earnings per share remained flat despite revenue growth. The telecommunications testing company trades at 26.2x forward P/E. Merck emerged as the recommended stock, boasting a 21.5% trailing 12-month free cash flow margin. The pharmaceutical company's portfolio includes the blockbuster cancer immunotherapy Keytruda. The analysis emphasises that strong cash flow alone doesn't guarantee superior returns without efficient capital allocation.

Channel NewsAsia
Jul 30th, 2026
Singapore group will develop 'most promising' Ebola vaccine.

Singapore group will develop 'most promising' Ebola vaccine. The Singapore-based Hilleman Laboratories announced it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. 30 Jul 2026 06:31PM (Updated: 30 Jul 2026 06:36PM) Add CNA as a trusted source to help Google better understand and surface our content in search results. Read a summary of this article on FAST. PARIS: A Singapore-based organisation announced on Thursday (Jul 30) it will develop an Ebola vaccine dubbed the "most promising" to fight back against a deadly outbreak in the Democratic Republic of Congo. Nearly 1,500 people have died in the conflict-wracked African country from the Bundibugyo strain of Ebola, for which there are no vaccines or treatments. But there are several different efforts racing to develop a vaccine for the previously rare strain in the hope of stemming the escalating outbreak. World Health Organization experts have said a single-dose shot based on the rVSV platform is the "most promising" candidate. This is because it uses the same platform as the only officially licensed Ebola vaccine Ervebo, which targets a different strain called Zaire. The Singapore-based Hilleman Laboratories announced on Thursday it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. The organisation is a joint venture between the US pharma giant MSD - known as Merck in North America - and the British charity Wellcome Trust. "We're racing to develop a Bundibugyo vaccine and make doses for clinical trials," Hilleman Laboratories CEO Raman Rao said in a statement. MSD developed and manufactured Ervebo and "will serve as a technical adviser" providing "expertise on the rVSV platform", the statement added. It was a joint statement with the Coalition for Epidemic Preparedness Innovations (CEPI), which has pledged funds to the rVSV shot and other Ebola vaccine efforts. If early trials are successful and the vaccine is authorised, CEPI and Hilleman said they hoped to "ensure rapid, affordable supply of doses in outbreak-affected countries and low- and middle-income settings". The Ervebo vaccine needs to be stored at ultra-low temperatures. However, the new Bundibugyo jab is hoped to last for months in normal refrigerators, making it cheaper and easier to deploy to remote areas. In May, WHO experts cautioned it would likely take seven to nine months before the rVSV vaccine is ready to be assessed in a clinical trial. The vaccine uses a modified version of the vesicular stomatitis virus, an animal virus, as a vector to deliver a protein from the Bundibugyo ebolavirus to the human immune system, triggering an immune response. The announcement comes a week after the first dose of a different Bundibugyo vaccine being developed by Oxford University was injected into a volunteer during a rapidly launched clinical trial. The epidemic in DR Congo is now the third-largest Ebola outbreak on record. There have been 3,360 confirmed cases, including 1,487 deaths since May, with the outbreak heavily centred on the northeastern Ituri province. Uganda, which borders Ituri, has seen 20 confirmed cases, including two confirmed deaths. A viral haemorrhagic fever, Ebola spreads through close contact and infected bodily fluids. Related topics.

Parrotainment
Jul 28th, 2026
H.I.V. Breakthrough: can Merck's new prevention pill reach the world's most vulnerable and what's at stake?

H.I.V. Breakthrough: can Merck's new prevention pill reach the world's most vulnerable and what's at stake? Merck's new H.I.V. prevention pill brings hope, but access concerns arise, with generic versions from Africa and India potentially costing as little as $5... Jul 28, 2026 - 22:31 The advent of a new H.I.V. prevention pill from Merck has ignited a beacon of hope in the fight against the virus, but concerns over access to this life-saving medication in vulnerable regions, particularly in Latin America, have sparked a global conversation. With companies in Africa and India set to produce generic versions that could cost as little as $5 per person per year, the question of accessibility versus affordability takes center stage. This breakthrough in H.I.V. prevention is not just a medical advancement but a potential game-changer in global health. The new pill, designed to prevent the transmission of the virus, represents a significant step forward in the battle against H.I.V., which has claimed millions of lives worldwide. However, the journey from the laboratory to the patient is fraught with challenges, especially in regions where healthcare infrastructure is weak and access to medications is limited. For individuals living with H.I.V. or at risk of infection, access to preventive measures like this new pill is a matter of life and death. The human cost of inaccessibility is not just measured in numbers of infections and deaths but in the impact on families, communities, and societies as a whole. The economic burden of untreated H.I.V. infections is also significant, affecting not just the individual but the broader economy. Key Challenges in Access Achieving universal access to this H.I.V. prevention pill will require a concerted effort from governments, pharmaceutical companies, health organizations, and communities worldwide. This includes negotiations over patent rights, investments in healthcare infrastructure, and public awareness campaigns to combat stigma and promote the use of preventive measures. The journey to ensuring that this life-saving medication reaches all who need it will be long and challenging, but the potential reward in lives saved and improved makes it a journey worth undertaking. As the world watches the rollout of this new H.I.V. prevention pill, the focus must remain on the ultimate goal: to make this and all life-saving medications accessible to everyone, everywhere. It is a challenge that requires not just medical innovation but a commitment to equity, justice, and the value of human life. **Will the production of generic versions of the H.I.V. prevention pill in Africa and India be enough to ensure global access, or are more drastic measures needed to combat patent protections and ensure equitable distribution?** Agree or disagree? The comment section is yours.